Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Accounts Payable
Apontis Pharma AG
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Accounts Payable
€5.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Accounts Payable
$4.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Accounts Payable
€7.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Merck KGaA
XETRA:MRK
|
Accounts Payable
€2.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Accounts Payable
€92.2m
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Accounts Payable
€9.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Accounts Payable?
Accounts Payable
5.1m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Accounts Payable amounts to 5.1m EUR.
What is Apontis Pharma AG's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
16%
Over the last year, the Accounts Payable growth was -5%. The average annual Accounts Payable growth rates for Apontis Pharma AG have been 16% over the past three years .
You don't have any saved screeners yet